Dalam jangka panjang, hal ini dapat menimbulkan penyakit perlemakan hati
The Healthletic BPC-157 supplement referenced throughout this article is not approved by the U.S
References FDA Multidiscipline Review (NDA 210557) NCBI Bookshelf LiverTox: Bremelanotide FDA Prescribing Information Vyleesi (bremelanotide) FDA Risk Assessment Review (CDER) for NDA 210557 Pfaus et al., 2022 The neurobiology of bremelanotide for the treatment of HSDD (review)
A survey commissioned by LloydsPharmacy Online Doctor (survey size n=2,000, of those 285 are current and active users of GLP-1s for weight loss and 216 have recently stopped) found that 28% (n=140) of those surveyed who were using or had previously used weight-loss injections had knowingly bought from unlicensed sellers, 12% (n=60) think they may have done, and 20% (n=100) bought drugs that are unlicensed and untested for weight loss in the UK
Response varies, and treatment should be monitored by a healthcare provider
A consistent estimate is better than no structure